Anterix Inc. filings document the company’s 900 MHz private wireless broadband spectrum business, including material-event reports on spectrum license sale agreements, operating and financial results, Regulation FD updates, and capital-structure disclosures. The records include disclosures tied to broadband license sales, narrowband-to-broadband license exchanges, spectrum clearing costs, contracted proceeds, and the Demonstrated Intent key performance indicator.
The company’s SEC filings also cover governance matters, executive compensation and severance arrangements, shareholder voting matters, risk factors, and regulatory developments affecting broadband use of the 900 MHz band. Material agreements involving its wholly owned subsidiary, PDV Spectrum Holding Company, LLC, are documented through Form 8-K exhibits and related event disclosures.
Anterix Inc. reported a leadership change, announcing that Chief Operating Officer Ryan Gerbrandt will leave the company effective January 9, 2026. His departure is tied to an internal reorganization in which the Chief Operating Officer position is being eliminated.
Subject to his signing a release of claims in favor of the company, Gerbrandt will receive severance benefits applicable to a Legacy Tier 1 Executive under Anterix’s Executive Severance Plan, as previously described in its 2025 proxy statement. This event reflects a structural change in the executive team rather than a disclosed change in the company’s financial outlook.
Anterix Inc. (ATEX) Chief Legal Officer and Corporate Secretary Gena L. Ashe reported a stock sale in a Form 4 filing. On 11/18/2025, she sold 6,564 shares of Anterix common stock at a price of $21.07 per share. After this transaction, she beneficially owns 13,366 shares of Anterix common stock directly.
Anterix Inc. reported a sharp turnaround to profitability for the quarter ended September 30, 2025. Net income was $53.5 million versus a $12.8 million loss a year ago, driven primarily by a $59.6 million non‑monetary gain from exchanging narrowband spectrum for broadband licenses and an $11.5 million gain on spectrum sales. Spectrum revenue was $1.6 million, essentially flat year over year.
Total assets rose to $420.4 million, including $325.3 million of intangible assets tied to spectrum. Deferred revenue reached $130.4 million, reflecting customer prepayments to be recognized over time, and remaining performance obligations were $178.5 million. Cash and cash equivalents were $39.1 million, with operating cash outflow of $1.7 million in the first half as gains were largely non‑cash.
The company advanced commercial deliveries, including transfers to LCRA and Oncor, and continued spectrum clearing and license exchanges. Operating expenses declined on lower G&A and product development costs, partially offset by severance related to workforce reductions.
Anterix Inc. furnished an update on its business performance, covering financial results and a key operating metric. The company announced its second quarter fiscal 2026 financial results for the three and six months ended September 30, 2025, and made the full earnings release available as an exhibit.
Anterix also posted an update on its "Demonstrated Intent" key performance indicator on its investor website, with that update likewise attached as an exhibit. Both the earnings release and the KPI update are furnished, not filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
Anterix Inc. (ATEX) disclosed insider equity activity by its CFO. On 09/29/2025, the officer received 11,405 restricted stock units. The grant vests 1/3 on September 29, 2026, with the remainder vesting in two equal annual installments thereafter.
On 10/04/2025, 404 shares were withheld at $22.55 to satisfy tax obligations tied to a partial RSU vest and settlement. Following these transactions, the officer directly owned 18,029 common shares.
Anterix Inc. (ATEX) filed a Form 3 for its Chief Financial Officer, reporting initial beneficial ownership as of 09/22/2025. The CFO holds 7,028 shares of common stock, which include Restricted Stock Units: 877 shares vesting on May 15, 2026; 672 shares vesting on July 12, 2026; and 3,925 shares vesting in three equal annual installments beginning October 4, 2025.
The filing also lists a stock option for 3,680 shares at an exercise price of $40, expiring on 04/03/2035, vesting in three equal annual installments beginning October 4, 2025.
Anterix Inc. (ATEX) reported an initial statement of beneficial ownership. A company officer filed Form 3 effective 09/17/2025, disclosing 34,578 shares of common stock held directly. The filer is identified as an Officer (Chief Marketing Officer) and Chief of Staff. The filing also notes Restricted Stock Units that will vest in three equal installments beginning on September 9, 2026.
Anterix Inc. disclosed that on October 3, 2025 it entered into a bonus agreement with Chief Regulatory and Communications Officer Christopher Guttman-McCabe. The company paid a one-time bonus of $500,000 on October 8, 2025 for his work supporting operations and strategy. The payment is subject to a clawback: if Mr. Guttman-McCabe leaves before October 3, 2027, he must repay the bonus. The agreement includes customary covenants and the company will file the full agreement as an exhibit in its periodic report for the quarter ended December 31, 2025.
Lang Scott A., President, CEO and Director of Anterix Inc. (ATEX), reported a personal purchase of company stock. On 09/18/2025 he acquired 4,650 shares of Common Stock at $21.28 per share and after the transaction beneficially owned 4,650 shares directly. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on the same date.
Anterix, Inc. (ATEX) disclosed a Chief Financial Officer transition: Timothy A. Gray resigned as CFO effective September 19, 2025, and the Board appointed Elena Marquez as CFO effective September 22, 2025. Ms. Marquez, age 39, has served as Vice President of Finance and Controller since September 2021 and previously held senior finance roles at Clinical Genomics and Prudential Financial. In connection with her promotion, she will receive additional restricted stock units with an aggregate grant date fair value of $250,000 vesting in three equal annual installments and will be eligible to participate in the Company’s Executive Severance Plan. The Board designated her as the company’s principal financial officer and principal accounting officer for SEC purposes. The filing notes standard indemnification and states there are no related-party or Item 404 transactions to disclose.